Jefferies analyst David Stanton downgrades Mesoblast (NASDAQ:MESO) from Buy to Hold.
Court Favors Vanda In Case Against FDA Over Detail Disclosure Of Rejection Of Sleep Disorder Drug
A federal court granted final judgment in favor of Vanda Pharmaceuticals Inc’s (NASDAQ:VNDA) Freedom of Information Act (FOIA) case requesting records created…